title: Terguride in stable Parkinson's disease.
abstract: Terguride (TER) (2 mg/day) was compared with a placebo in 41 stable Parkinson's disease (PD) patients, so as to test its efficacy as an add-on treatment to spare levodopa (LD). After the 4th week of add-on treatment, LD was reduced by about 25%. The number of "stable" patients (--those with an increase of no more than 20% of the basal Columbia University Rating Scale (CURS) score--remaining after LD reduction was used to compare the two add-on treatments. Most patients, remained "stable" in spite of LD reduction, and no significant differences between the therapies were discovered; the CURS score decreased over time only in the TER group. Hence, TER was shown to be a drug that has DA-ergic properties but with minimal antiparkinsonian efficacy.
authors.affiliation: Department of Neurology, Parkinson's Disease Centre, IRCCS C. Mondino, University of Pavia, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Martignoni
authors.forename: C
authors.initials: C
authors.lastname: Pacchetti
authors.forename: B
authors.initials: B
authors.lastname: Aufdembrinke
authors.forename: L
authors.initials: L
authors.lastname: Godi
authors.forename: G
authors.initials: G
authors.lastname: Albani
authors.forename: F
authors.initials: F
authors.lastname: Mancini
authors.forename: G
authors.initials: G
authors.lastname: Nappi
mesh_terms: D000368:Aged; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use; D008090:Lisuride / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos
chemical_list: D018491:Dopamine Agonists; D010919:Placebos; C006208:dironyl; D007980:Levodopa; D008090:Lisuride